Live IPO - Koligo Therapeutics Ltd.


Koligo Therapeutics Ltd (ASX: KOL) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc (Koligo) a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, in the United States.  Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Since 14 months ago, when sales commenced to a limited number of initial hospital customers, Koligo has generated revenues of approximately $1,600,000 from sales of this product.  

Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend the product’s shelf life and thus expand Koligo’s geographic reach. Koligo also seeks to develop and commercialize a range of other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders. Oversimplifying somewhat, pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.

  • Pay by: April 5

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus